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INCREASED DETECTION RATES OF INTERMEDIATE AND
HIGH-GRADE PROSTATE CANCER IN AFRICAN-AMERICAN MEN
AFTER 2012 USPSTF RECOMMENDATION AGAINST PSA
SCREENING
Jeffrey Arace*, Viktor Flores, Dennis Robins, Thomas Monaghan,
Andrew Winer, Jeffrey Weiss, Brooklyn, NY
INTRODUCTION AND OBJECTIVES: In 2012, the USPSTF
recommended to exclude prostate specific antigen (PSA) screening
from routine primary care for all patients. The Brooklyn VA Hospital
serves w50% African-American patients, who are more likely to
develop and die from prostate cancer (PCa) than the general
population. We compared the impact of the 2012 USPSTF
recommendation on PCa detection rates and biopsy patterns in
African-American patients and Caucasian patients.
METHODS: Demographics, PSA, transrectal ultrasonography
(TRUS) volume, and pathologic data were collected on patients who
underwent their first prostate biopsy at the Brooklyn VA Hospital be-
tween January 2007 and June 2018. The period from January 2007 to
May 2012 was considered pre-guideline, and the period from June 2012
to June 2018 was considered post-guideline. PCa detection rates and
biopsy patterns were compared using Chi-square testing.
RESULTS: 609 biopsies were analyzed pre-guideline (113 per
year), and 487 were analyzed post-guideline (81 per year), indicating a
28% decline in biopsy rate. There was no significant difference in the
detection rates of low, intermediate, or high grade PCa in
Caucasians. In contrast, African-Americans were significantly more
likely to be diagnosed with PCa in the post-guideline group (56% vs.
66%, p[0.016), and significantly more likely to be diagnosed with
intermediate-high grade PCa (38% vs. 47%, p[0.038). Before the
2012 USPSTF recommendation, African-American and Caucasian
patients undergoing their first biopsy were equally likely to be
diagnosed with high-grade PCa (11% AA vs. 11% CA). After the
2012 decision, we found that African-Americans were 50% more
likely than Caucasians to be diagnosed with high-grade PCa on first
biopsy (10% AA vs. 15% CA, p[0.008).
CONCLUSIONS: Our study demonstrates that African-
American patients have been disproportionately impacted by the 2012
USPSTF recommendation against PCa screening. In the 6 years
following the recommendation, detection rates of intermediate-high
risk disease remained unchanged for Caucasian patients but have
increased significantly for African-Americans. Whether these
observations reflect improved selection of patients to biopsy or an
increased number of undiagnosed patients remains unclear. The
results of our study strongly support the role of routine PSA
screening, particularly in higher risk patients.
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IMPACT OF 2012 UNITED STATES PREVENTIVE SERVICES TASK
FORCE STATEMENT ON PROSTATE CANCER SCREENING,
DETECTION AND PRESENTATION IN MEN UNDER THE AGE OF 70
AT KAISER PERMANENTE NORTHERN CALIFORNIA
Joseph Presti*, Mill Valley, CA; Stacey Alexeeff, Brandon Horton,
Stephanie Prausnitz, Andrew Avins, Oakland, CA
INTRODUCTION AND OBJECTIVES: To determine how the
2012 United States Preventive Services Task Force (USPSTF) Prostate
Cancer Screening recommendations altered the rates of PSA
screening, prostate biopsy, incident prostate cancer detection, and
stage IV at presentation in screen-eligible men in Kaiser Permanente
Northern California (KPNC).
METHODS: This is a retrospective study spanning the years
2010 to 2015, in screen-eligible (over 400,000) KPNC members
(African American men ages 45-69 and all other men ages 50-69)
with no prior history of prostate cancer. We compared the annual
rates of PSA testing, prostate biopsy, age and race adjusted incident
prostate cancer detection, and age and race adjusted stage IV cancer
at presentation between the pre-guideline period, 2010 and 2011; and
the post-guideline period, 2014 and 2015.
RESULTS: Following the 2012 USPSTF statement, relative
screening rates declined 23.4% (95% CI 23.0-23.8%), biopsy rates
declined 64.3% (95% CI 62.9-65.6%), incident prostate cancer detec-
tion rates declined 53.5% (95% CI 50.1-56.7%) resulting in 1871 fewer
incident cancers detected, and metastatic cancer rates increased
36.9% (95% CI 9.5%-71.0%) resulting in 75 more incident stage IV
cancers detected.
CONCLUSIONS: Following the USPSTF 2012 Statement, PSA
screening, biopsy and incident prostate cancer detection rates signifi-
cantly decreased while rates of metastatic disease significantly
increased in men under the age of 70.
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